medigraphic.com
Boletín Clínico de la Asociación Médica del Hospital Infantil del Estado de Sonora

2006, Number 2

<< Back Next >>

Bol Clin Hosp Infant Edo Son 2006; 23 (2)

Utilidad del Ácido Ursodeoxicolico en Diferentes Hepatopatías.
Informe de 6 Casos

Sotelo CN, Romero MJA

Language: Spanish
References: 20
Page: 69-80
PDF size: 259.80 Kb.


ABSTRACT

In this paper we described the physiological basis to ursodeoxycholic acid use (UDCA), and we report six clinical cases and evolution of pediatric patients in which we used UDCA.


REFERENCES

  1. Poupon RE, Poupon R, Balkan B. Ursodeoxycholic acid for the long term treatment of primary biliary cirrhosis. N Eng J Med 1994; 330: 13427.

  2. Pharmaceuticals from animal and plant products XII biotech 6 Pharma from animals. nzic.org.nz/chemProcess/biotech.2005

  3. Valera MJM, Smok SG, Poniachick J, Oksenberg R, Silva GP, Ferrario B, Buckel EG, Braham JB. Cirrosis biliar primaria: experiencia de trece años en dos centros de referencia. Rev Med Chil 2006; 134: 46974.

  4. Fernández Velado S, Huber Ruano I, Aymerich I, Dulfot S, Casado J, Pastor Anglada M. Bile acids alter the subcellular localization of CNTZ and increase CNTZ related transport activity in liver parenchymal cells. Biochem J 2006; 395 (2): 33744.

  5. Hino A. Morita M. Une M, Fujimura K, Kuromato T. Effects of deoxycholic acid and its eprimers on lipid peroxidation in isolated rat hepatocytes Biochem J 2001; 129: 6839.

  6. Fujino T, Une M, Imanaka T, Inove K, Nishimaki Mogami T. Structureactivity relationship of bile acids and bile acid analgs in regard to FxR activation Joumal Lipid Research 2004; 45: 1328.

  7. Lee Yong K, Won Hojo, Kwon Ich, Kim YongHee, Jeong SY. Structural determination and anterior polarity of selfaggregates prepared from deoxycholic acidmodified chitosan in water. Macromolecules 1998; 31: 37883.

  8. Amii LA, Lawrence MR. Nutritional support of pediatric surgical patient. Curr op Pediatr 1999; 11(3): 23742.

  9. Gills L, Baldessano R. Anderson J. Primary sclerosing cholangitis. Last update, emedicine 2006 June26 section 110.

  10. Tung BY, Emond MJ, Haggitt RC. Ursodiol use in associated with lower prevalence neoplasia in patients with colitis and primary sclerosing cholangitis. Ann Inter Med 2001; 134(2): 8995.

  11. Charatcharoenwitthaya P, Lindor K. Current concept in pathogenesis primary biliary cirrhosis. Ann of Hepatol 2005; 4(3); 161175.

  12. Sotelo CN, López CG. Autoimmunetype chronic active hepatitis in children. A report of 23 cases at a hospital in northwestern México. Ann of Hepatol 2005; 4(4): 25560.

  13. Torita NH, Hayashi M, Watanabe T, Obinata K, Mayano T, Nakatu N. Ursodeoxycholic acid in the treatment of biliary atresia biomed pharmacother 1989; 43(1): 3741.

  14. Schwarz SM. Biliary atresia. Last Update emedicine. 2006, April 20, Section 111.

  15. Saksena S, Tandon RK. Ursodeoxycholic acid in the treatment of liver diseases. Posgrad Med J 1997; 73: 7580.

  16. Colombo C, Batterrati PM, Podda M. et al. Urosdeoxycholic acid for liver diseases associated with cystic fibrosis: a double blind multicenter trial. Hepatology 1996; 23: 148490.

  17. Pares A, Tresserras R, Nunez I, Cerralbo M, et al. Long term effects of ursodeoxycholic acid in primary biliary cirrhosis result a double bind controlled multicentric trial. J Hepatol 2000; 32: 5616.

  18. Angulo P. Treatment of nonalcoholic fatty liver disease. Ann Hepatol 2002; 1(1): 1219.

  19. Holoman J, Glasa J, Kasar J, et al. Serum markers of liver fibrosis in patients with non alcohol steatohepatitis (NASH) correlation to liver marphology and effect of therapy. J Hepatol 200; 32: 21018.

  20. Ceriani R, Bunati S, Marini L, et al. Ursodeoxycholic acid in the nonalcoholic steatohepatitis. Hepatology 1998; 28: 386A




2020     |     www.medigraphic.com